1. 110PImmune prognostic index (IPI) and hyper-progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in phase I trials (Ph1T): Can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios?. (23rd October 2018) Authors: Matos Garcia, I; Azaro, A; Viaplana, C; Hierro, C; Martin-Liberal, J; Brana, I; Gardeazabal, I; Gomila, P; Vieito Villar, M; Ochoa De Olza Amat, M; Elez Fernandez, E; Oliveira, M; Oaknin, A; Verdaguer, H; Navarro Mendivil, A; Alsina, M; Tabernero, J; Macarulla Mercade, T; Dienstmann, R; Garralda, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 128TiP VCN-01 plus durvalumab in subjects with recurrent/metastatic head & neck squamous cell carcinoma (R/M HNSCC): Phase I clinical trial. (15th December 2019) Authors: Jove, M; Braña, I; Taberna, M; Hernando-Calvo, A; Castro, J Brenes; Garralda, E; Serrahima, M Plana; Pujol, M Maños; Capella, G; Alemany, R; Blasi, E; Blasco, C; Piqueras, M Cascallo; Nin, R Mesia Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 143PTumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT). (23rd October 2018) Authors: Martin-Liberal, J; Pagliuca, F; Hierro, C; Viaplana, C; Muñoz Couselo, E; Capdevila, J; Matos, I; Fariñas Madrid, L; Zamora, E; Braña Garcia, I; Elez Fernandez, E; Ochoa De Olza Amat, M; Azaro, A; Alsina, M; Vieito Villar, M; Fasani, R; Tabernero, J; Garralda, E; Dienstmann, R; Nuciforo, P G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 1510TiPThe GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors. (23rd October 2018) Authors: Garralda, E; van Hoef, M; Ochsenreither, S; Gianni, L; Lorusso, D; Fiedler, W; Keilholz, U; Klinghammer, K; Dicke, C; Kebenko, M; Matos, I; Tabernero, J; Raspagliesi, F; Del Conte, G; Habel, B; Baumeister, H; Zurlo, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 167P Efficacy of cetuximab based chemotherapy after immunotherapy treatments (IT) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts). (15th December 2019) Authors: Hernando-Calvo, A; Mirallas, O; Marmolejo, D; Felip, E; Garralda, E; Javierre, G Villacampa; Feliu, B; Martínez, S; Gutierrez, R; Dienstmann, R; Braña, I Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 1841PRefining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability. (23rd October 2018) Authors: Matos Garcia, I; García Ruiz, A; Martin-Liberal, J; Hierro, C; Ochoa De Olza Amat, M; Viaplana, C; Mur, G; Vieito Villar, M; Brana, I; Azaro, A; Perez, C; Rodriguez Freixinos, V; Argiles, G; Oliveira, M; Felip Font, E; Muñoz-Couselo, E; Tabernero, J; Dienstmann, R; Garralda, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 22P Early changes in plasma cell-free DNA (cfDNA) as a predictive biomarker of immune checkpoint inhibitors (ICIs) efficacy. (15th December 2019) Authors: Garcia, I Matos; Moreno, A; Arenillas, C; Carbo, C Hierro; Munoz-Cosuelo, E; Martin-Liberal, J; Braña, I; Villar, M Vieito; Azaro, A; Gadea, O Saavedra Santa; Gonzalez, I Gardeazabal; Javier, R; Roger, B; Elez, E; Felip, E; Dienstmann, R; Gros, A; Tabernero, J; Toledo, R D A; Garralda, E Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 363OTreatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC). (24th November 2019) Authors: Lee, D H; Subbiah, V; Gainor, J F; Taylor, M H; Zhu, V W; Doebele, R C; Lopes, G; Baik, C; Garralda, E; Gadgeel, S M; Kim, D-W; Turner, C D; Palmer, M; Miller, S; Curigliano, G Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 376PDImpact of a molecular prescreening program (MPP) in the management of patients with non-glioblastoma brain tumors. (23rd October 2018) Authors: Benítez Montañez, J C; Vieito Villar, M; Hierro, C; Gonzalez Rodriguez, M; Matos, I; Braña Garcia, I; Suarez Rodriguez, C; Martinez Saez, E A; Perez-Gago, M C; Morales-Barrera, R; Ortiz, C; Suarez, C; Maldonado, X; Martinez-Ricarte, F; Auger, C; Azaro, A; Dienstmann, R; Carles, J; Garralda, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 66PAdapting a prescreening program to match molecular alterations in over 5, 000 patients' tumors with targeted agents and immunotherapies in early clinical trials over the last 8 years. (16th September 2018) Authors: Aguilar, S; Vivancos, A; Nuciforo, P; Viaplana, C; Ruiz-Pace, F; Sanchez, E; Rodon, J; Tabernero, J; Garralda, E; Dienstmann, R Journal: Annals of oncology Issue: Volume 29:Number 6(2018)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗